GALAPAGOS GENOMICS WKN: A0EAT9 ISIN: BE0003818359 Kürzel: GLPG Forum: Aktien Thema: Hauptdiskussion

Auch hier neues 52 Wochentief. 🙈

http://ih.advfn.com/stock-market/NASDAQ/galapagos-nv-GLPG/stock-news/85558245/galapagos-announces-new-data-supporting-rapid-symptom-improvement-and-sustained

Cso geht endlich. Nächstes Jahr Komplettexplosion

Gibts was neues ?

Aus den Earning Call vom Februar : ... And in January, we have highlighted a bit some key numbers in terms of our expectations for Jyseleca. We anticipate that we can make this a EUR0.50 billion product in the second half of this decade. We also anticipate that by then this can be a contribution margin of approximately 50%. And we've also highlighted that we think that this is going to be breakeven in 2024 after three years of investments. So that's -- that should give you some direction as to how we think our spend would evolve...  https://www.fool.com/earnings/call-transcripts/2021/02/19/galapagos-nv-glpg-q4-2020-earnings-call-transcript/?source=iedfolrf0000001

📌.🐢

Buy Deutsche Bank. Target 110 Euro

5 Mrd Cash und MK. Da ist das Kursziel aber sehr konservativ. Imo.

Oh, zu spät 😀

Galapagos Raised to Overweight at Barclays; PT 80 euros By Bloomberg Automation (Bloomberg) -- Barclays analyst Rosie Turner raised the recommendation on Galapagos NV to overweight from equal-weight. PT set to 80 euros, implies a 23% increase from last price. Galapagos average PT is 75.15 euros. Targets updated in the last 3 months range from 62 euros to 192.95 euros

https://boerse-social.com/page/newsflow/research-fazits_zu_aixtron_infineon_dermapharm_schaeffler_basf

Barclays hebt Galapagos auf Overweight: Ziel 80 € (69 €)

Dann nehmen wir halt die EU und Japan😃

Die US-Gesundheitsbehörde FDA hatte die Zulassung für Filgotinib in der Indikation Rheumatoide Arthritis (RA) abgelehnt.. Zumindest ein Hauptgrund

Wieso ging die Aktie damals so stark runter?

War wie du bei cytomx investiert... Hab die weiterhin auf dem Kieker